The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93
Cited by
Sorted by citations
Items 101–200 of 1,000
van Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Groot, C. A. U., & Sonneveld, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1663 · Cited by 123
Avet‐Loiseau, H., Fonseca, R., Siegel, D. S. D., Dimopoulos, M. A., Špıčka, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V. S., Mihaylov, G. G., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707596 · Cited by 121
Self-citationChan, W. K., Kang, S., Youssef, Y., Glankler, E. N., Barrett, E. R., Carter, A. M., Ahmed, E. H., Prasad, A., Chen, L., Zhang, J., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0649 · Cited by 120
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 118
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02815 · Cited by 114
Self-citationInfectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi, H., Chrobok, M., Gran, C., Lund, J., Gruber, A., Gahrton, G., Ljungman, P. T., Wagner, A. K., & Alici, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211927 · Cited by 114
Avet‐Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P. S., Palumbo, A. P., Cavo, M., Langer, C., et al. (2017) · Blood · doi:10.1182/blood-2017-06-791228 · Cited by 113
Self-citationUpdate on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelı́nek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 115
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
Thakurta, A., Ortiz, M., Blecua, P., Towfic, F., Corre, J., Serbina, N. V., Flynt, E., Yu, Z., Yang, Z., Palumbo, A. P., et al. (2019) · Blood · doi:10.1182/blood-2018-10-880831 · Cited by 112
Self-citationResistance to proteasome inhibitors and other targeted therapies in myeloma
Wallington-Beddoe, C. T., Sobieraj‐Teague, M., Kuss, B. J., & Pitson, S. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15210 · Cited by 112
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 113
Oberle, A., Brandt, A. P., Voigtlaender, M., Thiele, B., Radloff, J., Schulenkorf, A., Alawi, M., Akyüz, N., März, M., Ford, C. T., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161414 · Cited by 110
Immunotherapy in hematologic malignancies: past, present, and future
Im, A., & Pavletic, S. Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0453-8 · Cited by 112
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109
Multiple myeloma: an overview of management
Bird, S. A., & Boyd, K. D. (2019) · Palliative Care and Social Practice · doi:10.1177/1178224219868235 · Cited by 109
Chari, A., Romanus, D., Palumbo, A. P., Blazer, M. A., Farrelly, E., Raju, A., Huang, H., & Richardson, P. G. G. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.625 · Cited by 109
Self-citationManagement of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 110
Drgoňa, Ľ., Gudiol, C., Lanini, S., Salzberger, B., Ippolito, G., & Mikulska, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.022 · Cited by 107
Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 108
Self-citationGenetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 107
Gherardin, N. A., Loh, L., Admojo, L., Davenport, A. J., Richardson, K., Rogers, A. J., Darcy, P. K., Jenkins, M. R., Prince, H. M., Harrison, S. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22130-1 · Cited by 110
Management of cardiovascular risk in patients with multiple myeloma
Plummer, C., Driessen, C., Szabó, Z. R., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0183-y · Cited by 108
Self-citationAmatya, C., Pegues, M. A., Lam, N., Vanasse, D., Geldres, C., Choi, S. H., Hewitt, S. M., Feldman, S. A., & Kochenderfer, J. N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.008 · Cited by 106
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
Binder, M., Nandakumar, B. N., Rajkumar, S. V., Kapoor, P., Buadi, F. K., Dingli, D., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Leung, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01453-5 · Cited by 103
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0040-1 · Cited by 104
Self-citationCornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 102
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 102
Bhatt, P. K., Kloock, C., & Comenzo, R. L. (2023) · Current Oncology · doi:10.3390/curroncol30020179 · Cited by 105
Sun, C., Mahendravada, A., Ballard, B. C., Kale, B. J., Ramos, C. A., West, J., Maguire, T., McKay, K., Lichtman, E. I., Tuchman, S. A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26792 · Cited by 99
Development of CAR-T cell therapies for multiple myeloma
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B., & Kröger, N. (2020) · Leukemia · doi:10.1038/s41375-020-0930-x · Cited by 102
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Kurdi, A. T., Glavey, S. V., Bezman, N., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A. M., Detappe, A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0998 · Cited by 98
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Sherbenou, D. W., Aftab, B. T., Yang, S., Behrens, C. R., Wiita, A. P., Logan, A. C., Acosta‐Alvear, D., Hann, B. C., Walter, P., Shuman, M. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85856 · Cited by 97
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
García‐Guerrero, E., Gogishvili, T., Danhof, S., Schreder, M., Pallaud, C., Pérez‐Simón, J. A., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-03-770776 · Cited by 96
Self-citationB cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Tai, Y., & Anderson, K. C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1641196 · Cited by 94
Self-citationMagarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 92
Self-citationReview: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Geyer, M. B., & Brentjens, R. J. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.07.003 · Cited by 96
Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Eleutherakis‐Papaiakovou, E., Kanellias, N., Kastritis, E., Gavriatopoulou, M., Terpos, E., & Dimopoulos, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/7131802 · Cited by 92
Self-citationComte, D., Karampetsou, M. P., Yoshida, N., Kis‐Tóth, K., Kyttaris, V. C., & Tsokos, G. C. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40038 · Cited by 91
Corre, J., Perrot, A., Caillot, D., Belhadj, K., Hulin, C., Leleu, X. P., Mohty, M., Facon, T. T. F., Buisson, L., Souto, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020008346 · Cited by 90
Self-citationGain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
Hanamura, I. (2021) · Cancers · doi:10.3390/cancers13020256 · Cited by 93
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Perumal, D., Imai, N., Laganà, A., Finnigan, J. P., Melnekoff, D. T., Leshchenko, V. V., Solovyov, A., Madduri, D., Chari, A., Cho, H. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2309 · Cited by 92
Pazina, T., James, A. M., Macfarlane, A. W., Bezman, N., Henning, K. A., Bee, C., Graziano, R. F., Robbins, M. D. H., Cohen, A. D., & Campbell, K. S. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339853 · Cited by 88
Law, M. F., Ho, R., Cheung, C. K. M., Tam, L. H. P., Ma, K., So, C.-Y., Ip, B. Y. M., So, J., Lai, J. W.-Y., Ng, J., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6484 · Cited by 87
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 90
Clinical pharmacokinetics and pharmacodynamics of lenalidomide
Chen, N., Zhou, S., & Palmisano, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0432-1 · Cited by 86
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
van der Schans, J. J., van de Donk, N. W. C. J., & Mutis, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01362 · Cited by 88
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 88
Self-citationSiegel, D. S. D., Schiller, G. J., Samaras, C. J., Sébag, M., Berdeja, J. G., Ganguly, S., Matous, J., Song, K., Seet, C. S., Talamo, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0813-1 · Cited by 84
Self-citationLiu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Self-citationAL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 83
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
How I treat myeloma with new agents
Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 87
Self-citationAnti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1216 · Cited by 80
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabó, Z. R., & Garderet, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 81
Systemic amyloidosis: novel therapies and role of biomarkers
Nuvolone, M., & Merlini, G. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw305 · Cited by 79
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
Multiple myeloma with central nervous system relapse
Egan, P. A., Elder, P. T., Deighan, W. I., O’Connor, S. J. M., & Alexander, H. D. (2020) · Haematologica · doi:10.3324/haematol.2020.248518 · Cited by 76
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Flynt, E., Bisht, K. K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020) · Cells · doi:10.3390/cells9020287 · Cited by 79
Zhuang, J., Shirazi, F., Singh, R., Kuiatse, I., Wang, H., Lee, H. C., Berkova, Z., Berger, A., Hyer, M. L., Chattopadhyay, N., et al. (2019) · Blood · doi:10.1182/blood-2018-06-859686 · Cited by 73
Self-citationGarcía‐Guerrero, E., Götz, R., Doose, S., Sauer, M., Rodríguez‐Gil, A., Nerreter, T., Kortüm, K. M., Pérez‐Simón, J. A., Einsele, H., Hudecek, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0840-y · Cited by 73
Self-citationBispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Li, C., Xu, J. L., Luo, W., Liao, D., Xie, W., Wei, Q., Zhang, Y., Wang, X., Wu, Z., Kang, Y. J., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02065-x · Cited by 74
Bu, D., Singh, R., Choi, E., Ruella, M., Nuñez-Cruz, S., Mansfield, K. G., Bennett, P., Barton, N., Wu, Q., Zhang, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25359 · Cited by 74
Moreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 72
Self-citationRichardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71
Self-citationPaggio, J. C. D., & Tannock, I. F. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30338-9 · Cited by 75
Berdeja, J. G., Jagannath, S., Zonder, J. A., Badros, A. Z., Kaufman, J. L., Manges, R., Gupta, M., Tendolkar, A. V., Lynch, M. J., Bleickardt, E. W., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.12.007 · Cited by 70
Self-citationMultiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Fotiou, D., Gavriatopoulou, M., & Terpos, E. (2020) · Cancers · doi:10.3390/cancers12010191 · Cited by 69
Sobh, M. A. K., Michallet, M., Gahrton, G., Iacobelli, S., van Biezen, A., Schönland, S. O., Petersen, E. J., Schaap, N. P., Bonifazi, F., Volin, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.101 · Cited by 69
Self-citationRestoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
Pittari, G., Vago, L., Festuccia, M. B., Bonini, C., Mudawi, D., Giaccone, L., & Bruno, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01444 · Cited by 73
Mills, J. R., Kohlhagen, M., Willrich, M. A. V., Kourelis, T., Dispenzieri, A. A., & Murray, D. L. (2018) · Blood · doi:10.1182/blood-2018-05-848986 · Cited by 69
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationHou, J., Jin, J., Xu, Y., Wu, D., Ke, X., Zhou, D., Lu, J., Du, X., Chen, X., Li, J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0501-4 · Cited by 67
Self-citationGhobrial, I. M., Liu, C., Zavidij, O., Azab, A. K., Baz, R., Laubach, J. P., Mishima, Y., Armand, P. A., Munshi, N. C., Basile, F. G., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25627 · Cited by 67
Self-citationSLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis
Wu, Y., Wang, Q., Li, M., Lao, J., Tang, H., Ming, S., Wu, M., Gong, S., Li, L., Liu, L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci150224 · Cited by 67
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Magen, H., & Muchtar, E. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716652862 · Cited by 69
Self-citationSoluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Kikuchi, J., Hori, M., Iha, H., Toyama‐Sorimachi, N., Hagiwara, S., Kuroda, Y., Koyama, D., Izumi, T., Yasui, H., Suzuki, A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0525-6 · Cited by 67
A clinical perspective on plasma cell leukemia; current status and future directions
Tuazon, S. A., Holmberg, L., Nadeem, O., & Richardson, P. G. G. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00414-6 · Cited by 68
Self-citationMechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Yang, W., & Lin, S.-F. (2015) · BioMed Research International · doi:10.1155/2015/341430 · Cited by 69
Immune Therapies in Multiple Myeloma
Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 66
Self-citationHow I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Perugino, C. A., Mattoo, H., Mahajan, V. S., Maehara, T., Wallace, Z. S., Pillai, S. S., & Stone, J. H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40168 · Cited by 65
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J. L., Gharibo, M. M., Sher, T., Bojanini, L., Kirby, M. W., & Chanan-Khan, A. A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.018 · Cited by 65
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre‐Barbe, M., Lafon, I., Facon, T. T. F., Leleu, X. P., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65
Self-citationWhither Radioimmunotherapy: To Be or Not To Be?
Green, D. J., & Press, O. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2523 · Cited by 64
Immune-based therapies in the management of multiple myeloma
Zanwar, S., Nandakumar, B. N., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00350-x · Cited by 64
Elotuzumab for the treatment of multiple myeloma
Wang, Y., Sanchez, L. J., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0284-z · Cited by 65
Kazandjian, D. G., & Landgren, O. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.008 · Cited by 63
Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00695-5 · Cited by 62
Self-citationThe immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
Hoyos, V., & Borrello, I. (2016) · Blood · doi:10.1182/blood-2016-05-636357 · Cited by 62
The Danish National Multiple Myeloma Registry
Gimsing, P., Holmström, M. O., Klausen, T., Andersen, N. F., Gregersen, H., Pedersen, R. S., Plesner, T., Pedersen, P. T., Frederiksen, M., Frølund, U. C., et al. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99463 · Cited by 62
Gene Expression Profiles in Myeloma: Ready for the Real World?
Szalat, R. E., Avet‐Loiseau, H., & Munshi, N. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0867 · Cited by 64
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 65
Goldschmidt, H., Baertsch, M., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M., Hillengaß, J., Sauer, S., Müller‐Tidow, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0948-0 · Cited by 63
Solimando, A. G., Vià, M. D., Cicco, S., Leone, P., Lernia, G. D., Giannico, D., Desantis, V., Frassanito, M. A., Morizio, A., Tascon, J. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070997 · Cited by 61
Self-citationEmerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 63
BCMA in Multiple Myeloma—A Promising Key to Therapy
Kleber, M., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184088 · Cited by 63
Monoclonal antibody therapy in multiple myeloma
Touzeau, C., Moreau, P., & Dumontet, C. (2017) · Leukemia · doi:10.1038/leu.2017.60 · Cited by 61
Self-citation
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
